Archive for the 'Medical Patents' Category
September 29th, 2010 by admin
Genzyme Corp., a takeover target of Sanofi-Aventis SA, expects to complete sales of its diagnostics and pharmaceutical-ingredients units by the end of the year. Genzyme has six bidders for the drug business, Chief Financial Officer Michael Wyzga said today at an investor conference. Sale of the units will make Genzyme more appealing to potential buyers, said Michael Yee, with RBC Capital Markets.
Continue reading ‘Sanofi Target Genzyme More Attractive to Buyers With Unit Sales’
September 17th, 2010 by admin
Brian Orelli of The Motley Fool highlights four drugs–AstraZeneca’s Brilinta, Questcor’s Acthar Gel, Savient’s Krystexxa and Novartis’ Gilenia–that could gain FDA approval this month despite some previous difficulties. However, given recent troubles with other approved drugs, the FDA’s cautious nature could cause issues for some of the drugmakers.
Continue reading ‘Four Drugs Look to Pass FDA Muster this Month’
September 14th, 2010 by admin
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America’s biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.
Continue reading ‘Nearly 400 Medicines and Vaccines in Development to Fight Infectious Diseases’
September 8th, 2010 by admin
Purdue University researchers have developed a new type of pump for drug-delivery patches that might use arrays of “microneedles” to deliver a wider range of medications than now possible with conventional patches. The current “transdermal” patches are limited to delivering drugs that, like nicotine, are made of small hydrophobic molecules that can be absorbed through the skin, said Babak Ziaie, a professor of electrical and computer engineering and biomedical engineering.
Continue reading ‘New Pump Created for Microneedle Drug-Delivery Patch’
September 7th, 2010 by admin
The results suggest that a buildup of that chemical, called glutamate, may play a role in the mechanism of migraines. An international scientific team has identified for the first time a genetic risk factor associated with common migraines and say their research could open the way for new treatments to prevent migraine attacks.
Continue reading ‘First Genetic Link to Common Migraine Found’
August 27th, 2010 by admin
Drug counterfeiting has become a $200-billion business annually, according to the World Customs Organization. By some calculations, the counterfeiting trade has become more lucrative than the narcotics business. It’s a global problem. The World Health Organization estimates that counterfeit drugs make up ten percent of the drug market worldwide. And experts say that solving it–or at least stemming the tide–requires the participation of both government and industry.
Continue reading ‘Drug Counterfeiting – a $200 Billion Business’
August 25th, 2010 by admin
More drugs are hitting the recall list these days. As CNN Money reports, the number of recalls hit 1,742 last year–that’s an increase of 309 percent over 2008. “We’ve seen a trend where the last four years are among the top five for the most number of drug recalls since we began tallying recalls in 1988,” says Bowman Cox, managing editor of the Gold Sheet, a trade pub that analyzes FDA data. “That’s a meaningful development.”
Continue reading ‘Drug Recalls Hit All-Time High’
August 20th, 2010 by admin
In a bid to break out of its dependence on manufacturing and cheap labor, the Chinese government is planning to invest $1.5 billion into new drug development between 2011 and 2016. And biotechnology is one of seven emerging industries that the Asian powerhouse will use to spearhead the next big step in its economic development, according to a report in China’s 21st Century Business Herald.
Continue reading ‘China Plans to Bolster Biotech’
August 19th, 2010 by admin
The following listing is of the top U.S. generic companies based on sales from Jan-Dec 2009. In recent years, Big Pharma has begun to look beyond brand-name drugs to the generics market. With the rising costs of healthcare, governments and payers alike are pushing for increased generics usage. And Big Pharma companies like Novartis and Pfizer are paying attention, striking deals with generics companies and even building units of their own.
Continue reading ‘Top 10 Generic Drug Companies 2010′
August 18th, 2010 by admin
With Genzyme in the news, we’ve all been hearing plenty about the wave of M&A deals that’s been rolling through the world’s life sciences industry. Last year, Thomson Reuters tracked more than 1,400 such deals worth $206 billion worldwide, giving the Boston Globe the hard numbers it needs to assert that this is one trend that has yet to crest.
Continue reading ‘Biotech M&A Frenzy Shows no Sign of Slowing’
